Physician profile
Annie Cha
NPI 1437997905
$1,777.89
in general payments reported to CMS, 2019-2025
18 companies · $1,021 in 2025
The $1,021 reported for 2025 was more than what 87% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $757 · 2025: $1,021.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,778.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,777.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $281.45 | 2024-2025 | Farxiga |
| Actelion Pharmaceuticals US, INC. | $248.95 | 2024-2025 | Opsumit, Uptravi, Opsynvi |
| Novo Nordisk INC | $210.91 | 2024-2025 | Wegovy |
| Novartis Pharmaceuticals Corporation | $155.90 | 2025 | |
| Alnylam Pharmaceuticals INC. | $120.32 | 2024-2025 | Amvuttra |
| Abiomed | $113.39 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $86.25 | 2025 | |
| Pfizer INC. | $80.58 | 2024-2025 | |
| Amgen INC. | $70.41 | 2024-2025 | Repatha, Repatha |
| Merck Sharp & Dohme LLC | $64.35 | 2025 | Verquvo, Capvaxive |
| Esperion Therapeutics, INC. | $60.01 | 2025 | Nexletol |
| Boston Scientific Corporation | $57.53 | 2025 | Watchman Access System, Bodyguardian |
| Edwards Lifesciences Corporation | $56.86 | 2024-2025 | Sapien 3 Ultra Resilia |
| E.R. Squibb & Sons, L.L.C. | $50.43 | 2024-2025 | Camzyos |
| Boehringer Ingelheim Pharmaceuticals, INC. | $39.30 | 2024-2025 | Jardiance |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $33.04 | 2024 | Xarelto |
| Ionis Pharmaceuticals, INC. | $24.50 | 2025 | Tryngolza |
| Lantheus Medical Imaging, INC. | $23.71 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Annie Cha listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.